Polyethyleneimine-Modified Laminarin Nanoparticles: A Novel Vaccine Adjuvant Platform

Study Background and Research Question

Vaccines remain a cornerstone in the prevention and management of infectious diseases, but the limitations of conventional adjuvants—such as aluminum salts—have motivated the search for safer and more effective alternatives. Polysaccharide nanoparticles have garnered attention due to their biocompatibility and immunomodulatory properties. However, optimizing their delivery, cell uptake, and immunostimulatory capacity remains a significant challenge. The reference study (Yu et al., 2025) investigates whether polyethyleneimine (PEI)-modified laminarin nanoparticles can serve as a potent adjuvant for the model protein antigen ovalbumin (OVA), aiming to enhance both humoral and cellular immune responses in vitro and in vivo.

Key Innovation from the Reference Study

The core innovation lies in the rational functionalization of laminarin—a β-glucan polysaccharide from brown algae—by covalently grafting PEI chains onto its structure. This modification imparts a positive surface charge to the resulting cationic laminarin (CLam) nanoparticles, which facilitates antigen complexation and cellular internalization. When mixed with OVA, CLam forms stable nanoparticles (CLam/OVA) with an optimal particle size (~380 nm), uniform distribution, and improved colloidal stability. This design leverages the electrostatic attraction between the cationic carrier and negatively charged antigens or cell membranes, which enhances antigen delivery to antigen-presenting cells (APCs) and promotes efficient immune activation.

Methods and Experimental Design Insights

The researchers synthesized CLam by conjugating laminarin with branched PEI, followed by thorough physicochemical characterization of the resulting nanoparticles. Dynamic light scattering and electron microscopy confirmed a uniform particle size and morphology. CLam was then mixed with OVA to form antigen-loaded nanoparticles. Their biological activity was evaluated using in vitro assays with primary mouse bone marrow-derived dendritic cells (BMDCs), assessing uptake, maturation, and lysosomal escape. Key immunological endpoints included quantification of cytokine secretion, cell surface marker expression, and antigen cross-presentation. In vivo, mice were immunized with CLam/OVA, alum/OVA (as a conventional adjuvant control), or OVA alone, with subsequent measurement of OVA-specific antibody titers, cytotoxic T lymphocyte (CTL) responses, and cytokine profiles.

Protocol Parameters

• Nanoparticle formation: Mix PEI-modified laminarin (CLam) with OVA under mild agitation to achieve uniform CLam/OVA complexes (~380 nm diameter).
• Dendritic cell incubation: Expose BMDCs to CLam/OVA for 4–24 hours to assess uptake, maturation markers, and lysosomal escape using fluorescence microscopy and flow cytometry.
• Immunization schedule: Administer CLam/OVA, alum/OVA, or OVA alone to mice via intramuscular injection at days 0 and 14; collect serum and splenocytes at predefined time points for immunological assays.
• Lysosome labeling in live cells: Use a fluorescent lysosome probe such as Lyso-Tracker Red DND-99 (for example, at nanomolar concentrations) to visualize intracellular trafficking and antigen processing.

Core Findings and Why They Matter

The study demonstrates that CLam/OVA nanoparticles are more efficiently internalized by BMDCs compared to non-modified laminarin or alum-based formulations. The positive surface charge of CLam enhances cellular uptake and promotes lysosomal escape—a key step for antigen cross-presentation to CD8+ T cells. Mechanistically, CLam/OVA activates BMDCs via toll-like receptor (TLR2/4), cytokine, and chemokine signaling pathways, as evidenced by upregulated maturation markers and robust cytokine release. In vivo, CLam/OVA induces significantly higher OVA-specific IgG titers, stronger CTL responses, and increased IFN-γ secretion relative to alum/OVA or OVA alone. These data underscore the potential of PEI-functionalized polysaccharide nanocarriers to simultaneously boost humoral and cellular immunity—a critical requirement for next-generation vaccines targeting both infectious diseases and cancer.

Comparison with Existing Internal Articles

Several internal resources deepen the context for lysosome labeling and live-cell tracking workflows:

• The article "Lyso-Tracker Red: Advanced Lysosome Labeling in Live Cell..." highlights the specificity of Lyso-Tracker Red for intracellular acidic compartment visualization, which is central to tracking antigen processing and lysosomal escape in nanoparticle-based vaccine studies.
• "Lyso-Tracker Red: Transforming Lysosome Imaging for Innovation" provides guidance on using Lyso-Tracker Red DND-99 for advanced analysis of lysosomal distribution and morphology, supporting studies like the reference paper where the dynamics of antigen trafficking and lysosome escape are key mechanistic endpoints.
• "Strategic Lysosome Labeling: Insights for Translational Research" (link) further bridges the role of lysosomal probes in translational workflows, from immuno-oncology to vaccine design, underscoring the broad relevance of precise lysosome tracking in cellular immunology.

These resources collectively affirm that robust lysosome labeling in live cells is foundational for elucidating the intracellular fate of nanovaccines and their adjuvant functions.

Limitations and Transferability

While the CLam/OVA platform demonstrates marked improvements over traditional adjuvants in the murine OVA model, certain limitations remain. The immunological efficacy and safety profile of PEI-modified laminarin require further validation in diverse antigen systems, disease models, and higher species to support translational application. In addition, the long-term biodistribution, biodegradability, and potential toxicity of synthetic cationic polymers such as PEI—though mitigated by the laminarin backbone—should be systematically addressed. The study's focus on a model antigen (OVA) also means the findings may not fully predict performance with clinically relevant antigens or in human immune settings.

Research Support Resources

For researchers seeking to replicate or extend these workflows, reliable tools for lysosome labeling in live cells are essential. Lyso-Tracker Red (SKU B8814) from APExBIO offers high-specificity fluorescent labeling of lysosomes, supporting detailed analysis of antigen trafficking, lysosomal distribution, and morphology in live-cell imaging and flow cytometry. Used at nanomolar concentrations, Lyso-Tracker Red DND-99 enables precise tracking of nanoparticle-mediated antigen delivery and lysosomal escape, complementing the mechanistic investigations described in this and related studies. For best results, users should follow product guidelines regarding storage, concentration, and live-cell compatibility.